Challenges With Off-Label Bevacizumab Use in Retinal Diseases

Michael A. Klufas, MD, discusses issues with off-label bevacizumab use, focusing on compounding issues and decreases in clinical efficacy due to repackaging.

Related Keywords

Michaela Klufas , ,Szilard Kiss ,Pine Pharmacies ,Biosimilars ,Ophthalmology ,Wet Amd ,Age Related Macular Edema ,Off Label Bevacizumab ,Compounded Medications ,Reduced Clinical Efficacy ,Lytenava ,